In 2018 Wang and colleagues [23] analyzed the peripheral blood samples from 61 CML patients who presented an undetectable level of BCR-ABL by qPCR after tyrosine kinase inhibitor (TKI) treatment in three successive analyses performed once every 3 months. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.